Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Genflow Biosciences Plc ( (GB:GENF) ) is now available.
Genflow Biosciences Plc has signed two Confidential Disclosure Agreements with leading animal health companies to explore potential collaborations in advancing its SIRT6-centenarian gene therapy platform. These agreements are part of Genflow’s strategy to leverage its proprietary technology for both human and animal health, particularly in the growing market of companion animals. The collaborations aim to accelerate commercialization, enhance market penetration, and maximize shareholder value by combining Genflow’s innovative science with the resources of large pharmaceutical partners. This move reflects strong industry interest and strengthens Genflow’s pathway to potential licensing agreements and future commercialization.
More about Genflow Biosciences Plc
Genflow Biosciences Plc, founded in 2020 and headquartered in the UK with R&D facilities in Belgium, is a biotechnology company focused on pioneering gene therapies to slow down the aging process. The company aims to promote longer and healthier lives while addressing the impacts of a growing aging population. Genflow’s lead compound, GF-1002, involves the delivery of a centenarian variant of the SIRT6 gene, showing promising preclinical results. The company is conducting a 12-month clinical trial on aged dogs and plans to explore the benefits of GF-1002 in treating MASH, a prevalent chronic liver disease.
Average Trading Volume: 6,204,564
Technical Sentiment Signal: Sell
Learn more about GENF stock on TipRanks’ Stock Analysis page.